Study results will be presented at the 14th International Conference on Advanced Technologies and Treatments for Diabetes
NEW YORK, June 4, 2021 / PRNewswire / – DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, today announced that it will be presenting the results of a new study at the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2021; 2nd-5th June 2021).
The study, titled “Impact of Digital Intervention Engine on Diabetes Self-Management,” examined the impact of DarioHealth’s highly personalized digital travel on both clinical outcomes and engagement outcomes, and applied custom digital behavior change intervention workflows to address that Increase user digital engagement.
This new study is a retrospective study of 246 DarioHealth users and presents several powerful results obtained by the users:
- The percentage of users who measured blood glucose was significantly higher in the test group of 127 Dario users who received interventions controlled by the digital intervention machine: 14% in the first 30 days and 22% in 30-60 Days;
- The average number of blood glucose measurements increased by 6% and 17% and 30-60 days in the first 30 days; and
- The recurrence time (average number of days between blood sugar measurements) was significantly improved by 30% in the test group.
Most digital health solutions are personalized by applying generalized predictions to groups of “like” participants who do not adapt to the truly unique needs of each participant. Dario’s study found that personalizing clinical interventions in response to unique individual circumstances enabled by a powerful combination of AI, dynamically personalized user guidance, coaching, and behavioral research helped increase self-monitoring and platform engagement with inconsistent users to improve permanently.
“The potential benefits of this research could be life-changing for so many people,” said Dr. Yifat Hershcovitz, Ph.D., Scientific and Clinical Director at DarioHealth and one of the authors of the study. “In the context of everyday busy life, simply remembering to take blood glucose tests at reasonable intervals can be challenging. The results of this study confirm that DarioHealth’s platform and hyper-personalized approach make it much easier for people to remember to incorporate glucose measurement into their daily lives in order to improve and maintain health outcomes. “
“We believe that diabetes self-management is ripe for innovation, and our research shows the important role a digital intervention engine can play in helping people get involved in their diabetes management,” said Dr. Omar Manejwala, Chief Medical Officer of DarioHealth. “DarioHealth prides itself on our work to deliver a sustainable and impactful digital therapeutic solution, and these latest insights only complement our strong evidence that our hyper-personalized approach produces real, measurable improvements.”
DarioHealth is presenting additional research results at the ATTD with the title “Impact of a Digital Therapeutic on Insulin Self-Management”. For registration inquiries and additional information on ATTD 2021, visit ATTD.kenes.com. Participation is welcome and encouraged for everyone. Registration is reduced, as the conference will take place virtually this year.
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a global leader in digital therapeutics, revolutionizing the way people with chronic illnesses manage their health. The next generation of AI-based digital therapy solutions from Dario support more than just the individual illness. Dario offers adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, quality software, and coaching to help individuals improve their health and achieve meaningful outcomes. Dario offers one of the top rated diabetes and high blood pressure solutions on the market. Working at the intersection of life sciences, behavioral sciences and software technology, the company’s cross-functional team is rapidly expanding into new chronic disease and geographic markets, using a performance-based approach to improving the health of its users. Dario makes the right thing easy. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and related statements by representatives and partners of DarioHealth Corp. contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts can be considered forward-looking statements. Without limiting the generality of the foregoing, words such as “plan”, “project”, “potentially”, “seek”, “may”, “will”, “expect”, “believe”, “anticipate”, “intend”, “May”, “estimate” or “continue” are intended to identify forward-looking statements. For example, in this press release the company uses forward-looking statements when discussing the study results that the potential benefit of the study results could be life-changing for so many people that diabetes- Self-management is ripe for innovation, and that the results add to its strong evidence that our hyper-personalized approach produces real, measurable improvements. Readers are cautioned that certain important factors can, and could cause, actual results for the company material differ from any forward-looking statements in this press release hen. Factors that may affect the company’s results include, but are not limited to, regulatory approvals, product demand, market acceptance, the effects of competitive products and prices, product development, commercialization or technological difficulties, success or failure of negotiations and trade, legal, social and economic risks and risks related to the adequacy of the cash available. Additional factors that could cause or contribute to differences between the company’s actual results and forward-looking statements include, but are not limited to, the risks described in the company’s filings with the United States Securities and Exchange Commission. Readers are cautioned that actual results (including, but not limited to, the timing and results of the company’s commercial and regulatory plans for Dario ™) could differ materially from those set forth in the forward-looking statements. The company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or for any other reason, unless required by applicable law.
DarioHealth corporate contact:
Suzanne Bedell
VP Marketing
[email protected]
+ 1-347-767-4220
Media contact:
Josephine Galatioto
[email protected]
+1 212-845-4262
SOURCE DarioHealth Corp.
